Research dossier
Clinical research on GSH
8 trials reviewed across 5 indications.
Strongest evidence
Raising body glutathione stores and immune markers
Mechanism
Glutathione is the body's primary intracellular antioxidant and a substrate for immune-cell function. Raising stores is proposed to support NK and T-cell activity.
Chronic dosing of well-formulated glutathione (Setria 1000 mg/day over 6 months) raised blood GSH ~30–35% and doubled NK-cell cytotoxicity; liposomal forms show similar signals. But a single dose does nothing (Witschi) and plain oral GSH did not move oxidative-stress markers in 4 weeks (Allen). Form, dose, and duration decide whether it works.
The convincing trials are manufacturer-funded and measured biomarkers, not clinical outcomes. 'Raises NK-cell activity' is not the same as 'prevents illness.'
Trials cited
Oral glutathione on body stores (Setria)
positive · RCT
Richie et al., 2015, European Journal of Nutritionn=54Industry-fundedThe trial that revived oral glutathione. Over 6 months, blood GSH rose at both doses; at 1000 mg/day, GSH increased ~30–35% in erythrocytes, plasma, and lymphocytes (and ~260% in buccal cells), with NK-cell cytotoxicity roughly doubled. Chronic dosing, unlike a single dose, does build body stores.
Funded by Kyowa Hakko, the Setria manufacturer, and uses their branded ingredient. The biomarker increases are real and well-measured, but it did not test downstream clinical outcomes (disease, symptoms) — only that levels and one immune marker rose.
Liposomal glutathione on body stores and immune markers
positive · Pilot
Sinha et al., 2018, European Journal of Clinical Nutritionn=12Industry-fundedA 1-month pilot found liposomal glutathione raised body GSH stores and improved markers of immune function and oxidative stress. Supports the idea that phospholipid encapsulation helps the tripeptide survive the gut.
Pilot study, only 12 participants, 1 month, run by investigators tied to glutathione delivery research (same Penn State group as the Setria trial). Hypothesis-generating, not confirmatory.
Systemic availability of oral glutathione
Null · Pilot
Witschi et al., 1992, European Journal of Clinical Pharmacologyn=7The foundational honesty check. A single 3 g oral dose did not significantly raise plasma glutathione, cysteine, or glutamate over 270 minutes. The authors concluded systemic availability of oral glutathione is negligible — the gut breaks the tripeptide down before it reaches the blood.
Tiny sample and a single acute dose. It does not address chronic dosing or modern delivery forms, but it set the long-standing skepticism about plain oral GSH.
Oral glutathione and oxidative-stress biomarkers
Null · RCT
Allen & Bradley, 2011, Journal of Alternative and Complementary Medicinen=40A clean double-blind RCT: 1000 mg/day of oral glutathione for 4 weeks produced no significant change in oxidative-stress biomarkers or glutathione status versus placebo. The 'master antioxidant in a pill lowers your oxidative stress' claim did not hold up here.
Plain reduced glutathione, only 4 weeks, in already-healthy adults with normal baseline status — exactly the population least likely to show a benefit. Longer trials with better-absorbed forms tell a more favorable story.
Antioxidant support and detoxification
Mechanism
Glutathione drives Phase II hepatic conjugation and quenches reactive oxygen species — the basis of the 'master detoxifier' marketing.
Mechanistically central, clinically oversold. An independent oral-GSH RCT found no change in oxidative-stress markers in healthy adults. Where antioxidant/liver benefits do show up (e.g. in deficiency or NAFLD), they more reliably come from precursors like NAC than from swallowing glutathione itself.
Most likely to matter in genuinely depleted or oxidatively-stressed people; little signal in already-healthy adults. 'Detox' claims are marketing language, not a clinical endpoint.
Oral glutathione and oxidative-stress biomarkers
Null · RCT
Allen & Bradley, 2011, Journal of Alternative and Complementary Medicinen=40A clean double-blind RCT: 1000 mg/day of oral glutathione for 4 weeks produced no significant change in oxidative-stress biomarkers or glutathione status versus placebo. The 'master antioxidant in a pill lowers your oxidative stress' claim did not hold up here.
Plain reduced glutathione, only 4 weeks, in already-healthy adults with normal baseline status — exactly the population least likely to show a benefit. Longer trials with better-absorbed forms tell a more favorable story.
Glutathione synthesis restored by cysteine + glycine
positive · RCT
Sekhar et al., 2011, American Journal of Clinical Nutritionn=16Elderly subjects were glutathione-deficient because they lacked the precursor amino acids cysteine and glycine. Supplying those precursors raised glutathione concentration ~95% and synthesis rate dramatically, and cut oxidative stress — restoring youthful levels. The key honest implication: feeding the building blocks works.
This trial supplemented precursors, NOT oral glutathione. It is included to make the honest point that the most reliable route to raise glutathione is NAC/glycine (and GlyNAC), not swallowing the intact tripeptide.
Glycemic control in diabetes
Mechanism
Diabetes depletes glutathione and elevates oxidative stress; restoring GSH may reduce oxidative damage and modestly improve glycemic markers.
One 6-month add-on trial in type 2 diabetics found 500 mg/day raised GSH, lowered the oxidative-stress marker 8-OHdG, and reduced HbA1c — most clearly in patients over 55. Promising in an older, depleted population, but the open-label design limits confidence.
Adjunct to standard diabetes treatment, never a replacement. Effect concentrated in older patients; needs blinded replication.
Long-term glutathione in elderly type 2 diabetes
positive · RCT
Kalamkar et al., 2022, Antioxidantsn=125Added to standard diabetes care, 500 mg/day raised blood GSH and lowered the oxidative-stress marker 8-OHdG within 3 months. HbA1c fell and fasting insulin rose, with the clearest effect in patients over 55. Suggests benefit may concentrate in older, oxidatively-stressed, depleted populations.
Open-label add-on design (the GSH group was not blinded to placebo), single center. The biomarker shifts are convincing; the glycemic effect needs blinded replication before being treated as established.
Skin lightening / brightening
Mechanism
Glutathione shifts melanin synthesis toward lighter pheomelanin and inhibits tyrosinase, the proposed route to a lighter, more even complexion.
A real but weak and narrow evidence base. One small Thai RCT (60 students, 4 weeks) showed melanin index dropped significantly at only two of six measured sites. Most skin-whitening evidence is small, short, and Asian-market-driven, with no long-term safety data.
Studied mainly in higher-melanin (Asian) populations over weeks, not years. Long-term safety of glutathione for cosmetic skin lightening is unestablished; IV glutathione for whitening is explicitly discouraged by regulators.
Oral glutathione as a skin-whitening agent
mixed · RCT
Arjinpathana & Asawanonda, 2012, Journal of Dermatological Treatmentn=60Melanin index fell at all six sites with glutathione, but reached statistical significance over placebo at only two (the right face and sun-exposed left forearm). A small, short, single-population study showing a modest, partial skin-lightening signal.
Only 60 subjects, 4 weeks, single Thai cohort, and significant at just two of six sites. Long-term safety of using glutathione for skin lightening is not established, and most evidence in this space is low-quality and Asian-market-driven.
Anti-aging and general antioxidant status
Mechanism
Glutathione declines with age as precursor availability falls; restoring it lowers oxidative stress and may support mitochondrial function.
Aging genuinely lowers glutathione, and restoring it lowers oxidative stress — but the trial that showed this used precursors (NAC + glycine), not oral glutathione. The honest takeaway: the building-block approach has the cleaner mechanistic evidence for raising GSH in older adults.
Benefit is for the genuinely depleted (older adults); the supporting data is for precursors, not the intact tripeptide. No evidence oral GSH 'reverses aging.'
Glutathione synthesis restored by cysteine + glycine
positive · RCT
Sekhar et al., 2011, American Journal of Clinical Nutritionn=16Elderly subjects were glutathione-deficient because they lacked the precursor amino acids cysteine and glycine. Supplying those precursors raised glutathione concentration ~95% and synthesis rate dramatically, and cut oxidative stress — restoring youthful levels. The key honest implication: feeding the building blocks works.
This trial supplemented precursors, NOT oral glutathione. It is included to make the honest point that the most reliable route to raise glutathione is NAC/glycine (and GlyNAC), not swallowing the intact tripeptide.
5 forms of GSH compared
Setria® (Kyowa Hakko)
Setria reduced glutathione
Raises blood GSH ~30–35% at 1000 mg/day over 6 months
Best forThe form with the strongest human trial (Richie 2015) for building body storesThe only oral glutathione ingredient with a 6-month RCT showing measurable increases in tissue GSH and immune markers. Manufacturer-funded, but the data is the best available for oral GSH.
immune250–1000 mgLiposomal glutathione
Phospholipid encapsulation improves survival through the gut; higher cellular uptake in head-to-head models
Best forBuilding GSH stores when gut degradation is the concernPilot human data (Sinha 2018) is encouraging but small. The phospholipid carrier is the rationale for choosing it over plain oral GSH.
S-acetyl glutathione
Acetylated for stability through the GI tract; proposed to reach cells intact
Best forStable oral delivery resistant to gut degradationMechanistically attractive but has the thinnest direct human-trial base of the better-absorbed forms. Reasonable, but do not assume it outperforms Setria — that comparison has not been run.
Reduced glutathione (plain oral)
Poor as a single dose; modest with chronic high-dose use
Best forGeneric oral glutathioneA single 3 g dose did not raise plasma GSH (Witschi 1992), and 1000 mg/day for 4 weeks did not move oxidative-stress markers (Allen 2011). Chronic high-dose use can build stores, but this is the form most undercut by gut degradation.
L-glutathione (standard oral)
Largely degraded by gut peptidases and gamma-glutamyltransferase before absorption
Best forThe cheapest and most common label formFunctionally the same caveats as plain reduced glutathione. If a budget product lists only 'L-glutathione' with no encapsulation or Setria branding, expect minimal systemic delivery from any single dose.
Are you deficient? Symptoms, risk groups, lab tests
Glutathione synthesis falls with age, in diabetes, in liver disease, and in HIV — largely because the precursor amino acids cysteine and glycine become limiting.
Common symptoms
- Elevated oxidative-stress markers (F2-isoprostanes, 8-OHdG)
- Impaired hepatic detoxification capacity
- Increased susceptibility to oxidative tissue damage
Who is at risk
Older adults
Reduced availability of cysteine and glycine lowers glutathione synthesis rate, raising oxidative stress (Sekhar 2011).
People with type 2 diabetes
Hyperglycemia-driven oxidative stress depletes glutathione; supplementation raised GSH and lowered 8-OHdG in trial subjects.
People with chronic liver disease or NAFLD
Hepatic glutathione is consumed faster under oxidative and conjugation load.
People with HIV or chronic inflammatory disease
Chronic inflammation and precursor depletion lower glutathione synthesis.
Lab markers
Whole-blood / erythrocyte glutathione
Not a routine clinical test; mostly used in research. Glutathione status is more often inferred from oxidative-stress markers than measured directly.
Better:Urinary F2-isoprostanes, 8-OHdG, GSH:GSSG ratio (research labs)
Side effects and drug interactions
Side effects
Generally well tolerated (oral)
Common
Oral glutathione was well tolerated in trials up to 1000 mg/day for 6 months, with no serious adverse events attributable to it. Mild GI complaints (bloating, loose stools) are occasionally reported.
Possible lower antioxidant enzyme activity (long-term high dose)
Uncommon
The Setria trial noted a decrease in some antioxidant enzyme activity after stopping high-dose supplementation, hinting at homeostatic adjustment with sustained high intake.
Serious adverse events with IV glutathione (skin whitening)
Severe
Intravenous glutathione marketed for skin lightening has been linked to Stevens-Johnson syndrome, thyroid dysfunction, kidney issues, and air-embolism / infection risk from injection. Regulators (including the Philippine FDA) have warned against off-label IV use.
Worse with:intravenous glutathione
Drug interactions
Other
chemotherapy agents (e.g. cisplatin)As an antioxidant, glutathione could theoretically blunt the pro-oxidant mechanism of some chemotherapies — though it has also been studied to reduce cisplatin neurotoxicity.
Do not take glutathione during cancer treatment without oncologist approval.
Combined-effect risk
acetaminophen (paracetamol) — via NACGlutathione (and its precursor NAC) detoxifies the toxic acetaminophen metabolite NAPQI; NAC is the established antidote in overdose.
Relevant context, not a self-treatment instruction — acetaminophen overdose is a medical emergency treated with NAC, not OTC glutathione.
Other critical caveats
- Plain oral glutathione is largely degraded in the gut. A single 3 g dose did not raise plasma GSH (Witschi 1992), and 1000 mg/day of plain oral GSH for 4 weeks did not change oxidative-stress markers (Allen 2011). Form and duration matter enormously.
- The positive oral-glutathione trials (Setria, liposomal) are manufacturer-funded and measured biomarkers — raised blood levels and NK-cell activity — not hard clinical outcomes. 'Raises glutathione' is not the same as 'makes you healthier.'
- The most reliable way to raise body glutathione is to supply its precursors (NAC and glycine), not to swallow the intact tripeptide — the precursor trial (Sekhar 2011) showed a ~95% rise in GSH.
- Skin-whitening evidence is weak: small, short, single-population oral trials. IV glutathione for skin lightening is off-label and has been linked to serious adverse events — avoid it.
- If you take oral glutathione, choose a better-absorbed form (Setria, liposomal, or S-acetyl). A budget capsule labeled only 'L-glutathione' will deliver little from any single dose.
Frequently asked
Does oral glutathione actually work, or is it destroyed in the gut?
Both, depending on how you take it. A single dose is destroyed in the gut — a 3 g dose did not raise plasma glutathione at all (Witschi 1992). But chronic dosing of a well-formulated product does build stores: Setria glutathione at 1000 mg/day for 6 months raised blood GSH ~30–35% and doubled NK-cell activity. Plain cheap oral glutathione is the form most likely to underdeliver.What's the best form of glutathione to take?
Setria (the form with a 6-month RCT), liposomal (phospholipid-encapsulated to survive the gut), or S-acetyl glutathione (acetylated for stability). Avoid relying on a budget capsule labeled only 'L-glutathione' or 'reduced glutathione' — these are the forms most undercut by gut degradation. Honestly, supplementing precursors like NAC is often the more reliable way to raise your own glutathione.Will glutathione whiten or brighten my skin?
The evidence is weak. One small Thai RCT (60 people, 4 weeks) found a significant drop in skin melanin at only two of six measured sites. Most skin-whitening studies are small, short, and from Asian markets, with no long-term safety data. IV glutathione marketed for whitening is off-label and has been linked to serious harms — do not use it.Is glutathione a 'master detoxifier' that cleanses my body?
Glutathione genuinely drives Phase II liver detoxification, but the 'detox cleanse' marketing overstates it. An independent oral-glutathione RCT found no change in oxidative-stress markers in healthy adults. Where antioxidant benefits do appear, they show up most reliably in depleted people (older adults, diabetics) and often come from precursors like NAC rather than oral glutathione itself.Is glutathione safe?
Oral glutathione is well tolerated up to 1000 mg/day for at least 6 months in trials. The real safety concern is intravenous glutathione marketed for skin lightening, which has been linked to Stevens-Johnson syndrome, thyroid and kidney problems, and injection-related risks — regulators have warned against it. If you are on chemotherapy, do not take glutathione without your oncologist's approval.
References
- 01Richie et al., 2015 — RCT of oral glutathione on body stores (PubMed)
- 02Witschi et al., 1992 — The systemic availability of oral glutathione (PubMed)
- 03Sekhar et al., 2011 — Deficient glutathione synthesis in aging, corrected by cysteine + glycine (PMC)
- 04Examine.com — Glutathione
Last reviewed2026-05-24